Intech Investment Management LLC Boosts Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Intech Investment Management LLC increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 74.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,499 shares of the company’s stock after acquiring an additional 13,057 shares during the period. Intech Investment Management LLC owned about 0.06% of Fulcrum Therapeutics worth $143,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Walleye Capital LLC bought a new stake in Fulcrum Therapeutics during the third quarter worth about $59,000. Bailard Inc. bought a new position in Fulcrum Therapeutics during the fourth quarter valued at approximately $169,000. Verition Fund Management LLC purchased a new position in shares of Fulcrum Therapeutics during the third quarter worth approximately $134,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $254,000. Finally, Centiva Capital LP purchased a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at $273,000. Institutional investors own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of “Hold” and an average price target of $8.63.

Fulcrum Therapeutics Trading Up 2.3 %

FULC stock opened at $3.09 on Friday. The stock has a market capitalization of $166.80 million, a price-to-earnings ratio of -9.97 and a beta of 2.20. The firm’s 50-day moving average price is $3.55 and its two-hundred day moving average price is $3.80. Fulcrum Therapeutics, Inc. has a 12-month low of $2.78 and a 12-month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.